In summary, the development of molecular inhibitors of the CRIP family has great potential in improving drug resistance, inhibiting tumor cell proliferation and metastasis, and may be used in combination with existing regimens to achieve personalized treatment for patients with cancer; however, the selectivity of targeting is still an important challenge in current research. This evidence concerns the gene CRIP2 and neoplasm.